3 completed, 2 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
Follow Afimmune: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease Epeleuton - Sickle Cell Disease | Phase 2 | Completed | Afimmune | 35 | 2024-01-10 | 2026-05-04 |
| Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes DS102, Placebo - Hypertriglyceridemia, Type 2 Diabetes | Phase 2 | Terminated | Afimmune | 233 | 2020-10-13 | 2023-06-12 |
| Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis 1000mg DS102 (BID) - Severe Acute Decompensated Alcoholic Hepatitis | Phase 2 | Terminated | Afimmune | 9 | 2018-11-28 | 2022-07-29 |
| Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease DS102, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | Afimmune | 49 | 2017-09-24 | 2020-01-31 |
| Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD Placebo capsules, Epeleuton - Non Alcoholic Fatty Liver Disease | Phase 2 | Completed | Afimmune | 96 | 2016-12-20 | 2022-10-12 |
Anemia, Sickle Cell (1) · Diabetes Mellitus, Type 2 (1) · Hypertriglyceridemia (1) · Non-alcoholic Fatty Liver Disease (1) · Pulmonary Disease, Chronic Obstructive (1)
epeleuton (3) · BID protein, human (1)
Georgia (3) · United States (3) · United Kingdom (2) · Canada (1) · Germany (1) · Israel (1) · Latvia (1) · Switzerland (1) · Ukraine (1)
Ian Pavord, MA DM FRCP FERS FMedSci (1) · Mark Thursz (1) · Markus Weissbach, MD (1) · Philip Newsome, MBChB, FRCPE, Ph.D (1)
2016 (1), 2018 (1)